Immuno-Biological Laboratories Co (TSE:4570) ROCE %: 16.94% (As of Mar. 2026)


TSE:4570 Immuno-Biological Laboratories Co Ltd TSE:4570
59 GF Score
Price 円969.00
GF Value 円576.66
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Immuno-Biological Laboratories Co ROCE %?

Immuno-Biological Laboratories Co TSE:4570 -2.02% 59 ROCE % is 16.94% as of Mar. 2026. GuruFocus rates TSE:4570 with a GF Score™ of 59/100 and a GF Value™ of 円576.66 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Immuno-Biological Laboratories Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.94%.

Immuno-Biological Laboratories Co  (TSE:4570) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Immuno-Biological Laboratories Co ROCE % Related Terms

Immuno-Biological Laboratories Co ROCE % Historical Data

* Premium members only.

The historical data trend for Immuno-Biological Laboratories Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuno-Biological Laboratories Co ROCE % Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.74 -21.02 9.89 14.44 17.54

Immuno-Biological Laboratories Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.84 9.45 19.85 18.47 16.94
TSE:4570
59GF Score
Immuno-Biological Laboratories Co Ltd TSE:4570
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immuno-Biological Laboratories Co ROCE % Calculation

Immuno-Biological Laboratories Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=301.895/( ( (1845.39 - 281.335) + (2155.121 - 276.194) )/ 2 )
=301.895/( (1564.055+1878.927)/ 2 )
=301.895/1721.491
=17.54 %

Immuno-Biological Laboratories Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=302.722/( ( (1965.744 - 269.861) + (2155.121 - 276.194) )/ 2 )
=302.722/( ( 1695.883 + 1878.927 )/ 2 )
=302.722/1787.405
=16.94 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.94% mean?
Immuno-Biological Laboratories Co (TSE:4570) has a ROCE % of 16.94% as of Mar. 2026.
Is Immuno-Biological Laboratories Co's ROCE % too high?
Immuno-Biological Laboratories Co's current ROCE % is 16.94%. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's ROCE % compare to VRTX and REGN?
Immuno-Biological Laboratories Co's ROCE % of 16.94% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Immuno-Biological Laboratories Co's current ROCE % is 16.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円576.66, compared to a current price of 円969.00 — trading 68% above its estimated fair value. The current ROCE % is 16.94%. Immuno-Biological Laboratories Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current ROCE % is 16.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?

Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued. The current stock price of 円969.00 is trading 68% above its estimated GF Value™ of 円576.66. GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.

Key valuation signals for TSE:4570:

  • ROCE %: 16.94%
  • GF Value™: 円576.66 vs. price of 円969.00 (68% above fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immuno-Biological Laboratories Co Business Description

Address 1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
59GF Score

Get the complete analysis for TSE:4570

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円969.00
Price
円576.66
GF Value